Impact of PCSK9 Inhibition on Proinflammatory Cytokines and Matrix Metalloproteinases Release in Patients with Mixed Hyperlipidemia and Vulnerable Atherosclerotic Plaque

被引:22
作者
Basiak, Marcin [1 ]
Kosowski, Michal [1 ]
Hachula, Marcin [1 ]
Okopien, Boguslaw [1 ]
机构
[1] Med Univ Silesia, Dept Internal Med & Clin Pharmacol, Med 18, PL-40752 Katowice, Poland
关键词
PCSK-9; inhibitors; atherosclerotic plaque; hyperlipidemia; interleukin-6; interleukin-18; tumor necrosis factor alfa; metalloproteinase; 2; PERIPHERAL ARTERIAL-DISEASE; HIGH-RISK; INFLAMMATION; INTERLEUKIN-18; THERAPY; PATHOGENESIS; PROGRESSION; EXPRESSION;
D O I
10.3390/ph15070802
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Atherosclerosis is a disorder in which, in addition to high cholesterol levels, several plasma factors play a significant role in its development. Among these cytokines and molecules are interleukin 6 (IL-6), interleukin 18 (IL-18), tumor necrosis factor alpha (TNF-alpha), metalloproteinase 2 (MMP-2), and metalloproteinase 9 (MMP-9), all of which may contribute to the stabilization of atherosclerotic plaque. The purpose of this study was to determine the effect of advanced lipid-lowering therapy on the levels of these determinants by utilizing proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors in patients with verified high-risk atherosclerotic plaque. Methods: The study involved patients with dyslipidemia who had the presence of unstable atherosclerotic plaque verified by ultrasonography and who were eligible to begin alirocumab treatment. The levels of IL-6, IL, 18, TNF-alpha, and MMPs were determined in this group before and after three months of therapy. After treatment, a statistically significant decrease in concentrations of Il-18, Il-6, TNF-alpha (p < 0.001) and MMP-2 (p < 0.05) was observed. Additionally, we observed that the concentrations of these markers were significantly higher in the group of patients prior to initiating therapy than in the control group. Our study's results suggest that PCSK-9 inhibitor therapy significantly reduces the concentration of factors influencing the stability of atherosclerotic plaque, which may explain their essential importance in reducing cardiovascular risk in patients receiving this treatment.
引用
收藏
页数:10
相关论文
共 52 条
[31]   Patterns of inflammation associated with peripheral arterial disease: The InCHIANTI study [J].
McDermott, MM ;
Guralnik, JM ;
Corsi, A ;
Albay, M ;
Macchi, C ;
Bandinelli, S ;
Ferrucci, L .
AMERICAN HEART JOURNAL, 2005, 150 (02) :276-281
[32]   From vulnerable plaque to vulnerable patient - A call for new definitions and risk assessment strategies: Part I [J].
Naghavi, M ;
Libby, P ;
Falk, E ;
Casscells, SW ;
Litovsky, S ;
Rumberger, J ;
Badimon, JJ ;
Stefanadis, C ;
Moreno, P ;
Pasterkamp, G ;
Fayad, Z ;
Stone, PH ;
Waxman, S ;
Raggi, P ;
Madjid, M ;
Zarrabi, A ;
Burke, A ;
Yuan, C ;
Fitzgerald, PJ ;
Siscovick, DS ;
de Korte, CL ;
Aikawa, M ;
Airaksinen, KEJ ;
Assmann, G ;
Becker, CR ;
Chesebro, JH ;
Farb, A ;
Galis, ZS ;
Jackson, C ;
Jang, IK ;
Koenig, W ;
Lodder, RA ;
March, K ;
Demirovic, J ;
Navab, M ;
Priori, SG ;
Rekhter, MD ;
Bahr, R ;
Grundy, SM ;
Mehran, R ;
Colombo, A ;
Boerwinkle, E ;
Ballantyne, C ;
Insull, W ;
Schwartz, RS ;
Vogel, R ;
Serruys, PW ;
Hansson, GK ;
Faxon, DP ;
Kaul, S .
CIRCULATION, 2003, 108 (14) :1664-1672
[33]   Effect of PCSK-9 Inhibitors on Lipid-Rich Vulnerable Coronary Plaque Assessed by Near-Infrared Spectroscopy [J].
Omori, Hiroyuki ;
Ota, Hideaki ;
Hara, Masahiko ;
Kawase, Yoshiaki ;
Tanigaki, Toru ;
Hirata, Tetsuo ;
Sobue, Yoshihiro ;
Okubo, Munenori ;
Kamiya, Hiroki ;
Matsuo, Hitoshi .
JACC-CARDIOVASCULAR IMAGING, 2020, 13 (07) :1639-1641
[34]   Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin [J].
Otake, Hiromasa ;
Sugizaki, Yoichiro ;
Toba, Takayoshi ;
Nagano, Yuichiro ;
Tsukiyama, Yoshiro ;
Yanaka, Ken-ichi ;
Yamamoto, Hiroyuki ;
Nagasawa, Akira ;
Onishi, Hiroyuki ;
Takeshige, Ryo ;
Nakano, Shinsuke ;
Matsuoka, Yoichiro ;
Tanimura, Kosuke ;
Kawamori, Hiroyuki ;
Shinke, Toshiro ;
Hirata, Ken-ichi .
JOURNAL OF CARDIOLOGY, 2019, 73 (3-4) :228-232
[35]   Carotid plaque surface irregularity predicts ischemic stroke - The Northern Manhattan Study [J].
Prabhakaran, Shyam ;
Rundek, Tatjana ;
Ramas, Romel ;
Elkind, Mitchell S. V. ;
Paik, Myunghee Cho ;
Boden-Albala, Bernadette ;
Sacco, Ralph L. .
STROKE, 2006, 37 (11) :2696-2701
[36]   PCSK9 induces a pro-inflammatory response in macrophages [J].
Ricci, Chiara ;
Ruscica, Massimiliano ;
Camera, Marina ;
Rossetti, Laura ;
Macchi, Chiara ;
Colciago, Alessandra ;
Zanotti, Ilaria ;
Lupo, Maria Giovanna ;
Adorni, Maria Pia ;
Cicero, Arrigo F. G. ;
Fogacci, Federica ;
Corsini, Alberto ;
Ferri, Nicola .
SCIENTIFIC REPORTS, 2018, 8
[37]   Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER Insights and Implications [J].
Ridker, Paul M. .
CIRCULATION, 2018, 137 (17) :1763-1766
[38]   Mechanisms of disease - Atherosclerosis - An inflammatory disease [J].
Ross, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (02) :115-126
[39]   Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort [J].
Saborowski, Michael ;
Doelle, Michael ;
Manns, Michael P. ;
Leitolf, Holger ;
Zender, Steffen .
CARDIOLOGY JOURNAL, 2018, 25 (01) :32-41
[40]   Serum or Plasma Matrix Metalloproteinase (MMP)-9 Levels and Cardiovascular Diseases [J].
Santana, Indiara V. ;
Tanus-Santos, Jose E. .
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2018, 11 (06) :524-525